Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Change

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Nov 03
2023
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
Learn More >
Nov 03
2023
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Learn More >
Nov 02
2023
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
Learn More >
Nov 02
2023
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
Learn More >
Oct 30
2023
Allogene Therapeutics Announces Participation in November Investor Conferences
Learn More >
Oct 26
2023
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
Learn More >
Oct 16
2023
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
Learn More >
Sep 27
2023
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Learn More >
Sep 05
2023
Allogene Therapeutics Announces Participation in September Investor Conference
Learn More >
Aug 14
2023
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Learn More >
View All